Bone Marrow-Derived Mesenchymal Stem Cells Have Innate Procoagulant Activity and Cause Microvascular Obstruction Following Intracoronary Delivery: Amelioration by Antithrombin Therapy
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Mesenchymal stem cells (MSCs) are currently under investigation as tools to preserve cardiac structure and function following acute myocardial infarction (AMI). However, concerns have emerged regarding safety of acute intracoronary (IC) MSC delivery. This study aimed to characterize innate prothrombotic activity of MSC and identify means of its mitigation toward safe and efficacious therapeutic IC MSC delivery post-AMI. Expression of the initiator of the coagulation cascade tissue factor (TF) on MSC was detected and quantified by immunofluorescence, FACS, and immunoblotting. MSC-derived TF antigen was catalytically active and capable of supporting thrombin generation in vitro. Addition of MSCs to whole citrated blood enhanced platelet thrombus deposition on collagen at arterial shear, an effect abolished by heparin coadministration. In a porcine AMI model, IC infusion of 25 × 106 MSC during reperfusion was associated with a decrease in coronary flow reserve but not when coadministered with an antithrombin agent (heparin). Heparin reduced MSC-associated thrombosis incorporating platelets and VWF within the microvasculature. Heparin-assisted therapeutic MSC delivery also reduced apoptosis in the infarct border zone at 24 hours, significantly improved infarct size, left ventricular (LV) ejection fraction, LV volumes, wall motion, and attenuated histologic evidence of scar formation at 6 weeks post-AMI. Heparin alone or heparin-assisted fibroblast control cell delivery had no such effect. Procoagulant TF activity of therapeutic MSCs is associated with reductions in myocardial perfusion when delivered IC may be successfully managed by heparin coadministration. This study highlights an important mechanistic insight into safety concerns associated with therapeutic IC MSC delivery for AMI. Stem Cells 2015;33:2726–2737
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Human mesenchymal stem cells modulate allogeneic immune cell responses
Aggarwal, S., & Pittenger, M. F. (2005) · Blood · doi:10.1182/blood-2004-04-1559 · Cited by 4,511
Gnecchi, M., He, H., Liang, O. D., Melo, L. G., Morello, F., Mu, H., Noiseux, N., Zhang, L., Pratt, R. E., Ingwall, J. S., et al. (2005) · Nature Medicine · doi:10.1038/nm0405-367 · Cited by 1,677
Dayan, V., Yannarelli, G., Billia, F., Filomeno, P., Wang, X.-H., Davies, J. E., & Keating, A. (2011) · Basic Research in Cardiology · doi:10.1007/s00395-011-0221-9 · Cited by 249
Cited by
Shattering barriers toward clinically meaningful MSC therapies
Levy, O., Kuai, R., Siren, E. M. J., Bhere, D., Milton, Y., Nissar, N., De Biasio, M., Heinelt, M., Reeve, B., Abdi, R., et al. (2020) · Science Advances · doi:10.1126/sciadv.aba6884 · Cited by 694
Homing and migration of mesenchymal stromal cells: How to improve the efficacy of cell therapy?
Becker, A. D., & Riet, I. V. (2016) · World Journal of Stem Cells · doi:10.4252/wjsc.v8.i3.73 · Cited by 460
Moll, G., Ankrum, J. A., Kamhieh-Milz, J., Bieback, K., Ringdén, O., Volk, H.-D., Geissler, S., & Reinke, P. (2019) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2018.12.006 · Cited by 440
“…rotational plasma-thromboelastometry (ROTEM) and thromboelastography, could be added to the current standards for MSC characterization [13,17 – 20, (ii) In Vivo Hemocompatibility Testing in Preclinical Animal Models In vitro assays are often paralleled by in vivo models [18,19,21,23,24].”
InfluentialMesenchymal Stromal Cell Therapeutic Delivery: Translational Challenges to Clinical Application
Caplan, H., Olson, S. D., Kumar, A., George, M., Prabhakara, K. S., Wenzel, P., Bedi, S., Toledano-Furman, N. E., Triolo, F., Kamhieh-Milz, J., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01645 · Cited by 306
Self-citationAdvancing application of mesenchymal stem cell-based bone tissue regeneration
Shang, F., Yu, Y., Liu, S., Ming, L., Zhang, Y., Zhou, Z., Zhao, J., & Jin, Y. (2021) · Bioactive Materials · doi:10.1016/j.bioactmat.2020.08.014 · Cited by 280
Metadata
- Authors
- Gleeson, B. M., Martin, K., Ali, M. T., Kumar, A. H. S., Pillai, M. G.-K., Kumar, S. P. G., O'Sullivan, J. F., Whelan, D., Stocca, A., Khider, W., Barry, F. P., O'Brien, T., & Caplice, N. M.
- Venue
- Stem Cells
- Publisher
- Oxford University Press (OUP)
- Published
- 2015-06-04
- Volume
- 33
- Issue
- 9
- Pages
- 2726-2737
- ISSN
- 1066-5099 (ISSN-L)
- 1549-4918
- OpenAlex
- W1936506769
- Cited by
- 116
- References
- 3
- FWCI
- 5.22
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.